Taeuber I, Weibel S, Herrmann E, et al. - Researchers examined if intravenous administration of tranexamic acid (TXA) is linked with thromboembolic events in patients of all ages and of any medical discipline. They searched Cochrane Central Register of Controlled Trials and MEDLINE for randomized clinical trials comparing intravenous TXA with placebo/no treatment. They identified a total of 216 eligible trials including 125,550 patients for inclusion in the analysis. They identified reporting of 1,020 (2.1%) thromboembolic events in the tranexamic acid group and 900 (2.0%) total thromboembolic events in the control group. No increased risk of any thromboembolic event was evident in patients of all medical disciplines. As intravenous TXA, irrespective of dosing, is not identified to be linked with increased risk of any TE, TXA is suggested as safe for use with undetermined utility for patients receiving neurological care.